Psychiatric disorders and mortality in patients with COVID-19

Takeaway

  • A diagnosis of schizophrenia spectrum disorder (SSD) constitutes a mortality risk factor in adult patients with coronavirus disease 2019 (COVID-19).

Why this matters

  • An increased incidence of COVID-19 among individuals with mental disorders has been reported; however, it is unclear which of these disorders is more closely associated, or likely to result in adverse COVID-related outcomes including mortality risk.

  • The association of SSD with increased COVID-19 mortality risk highlights the potential need for training for relevant mental health teams, to aid identification of COVID-associated symptoms and therefore necessary treatment, which may not be recognized by all patients, particularly those with active psychosis and/or cognitive impairment.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.